John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

Colites et immunothérapies des cancers Volume 24, numéro 8, Octobre 2017

  • [1] Hodi FS, O’Day SJ, Sosman JA, et al. IMPROVED SURVIVAL with IPILIMUMAB in patients with metastatic melanoma. N Engl J Med 2010 ; 363 : 711-23.
  • [2] Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011 ; 364 : 2517-26.
  • [3] Lynch T.J., Bondarenko I., Luft A. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer : results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30:2046-2054.
  • [4] Hodi F.S., Mihm M.C., Soiffer R.J. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA. 2003;100:4712-4717.
  • [5] Hodi F.S., Butler M., Oble D.A. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA. 2008;105:3005-3010.
  • [6] Yang J.C., Hughes M., Kammula U. Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis. J Immunother. 2007;30:825-830.
  • [7] Fong L., Kwek S.S., O’Brien S. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 2009;69:609-615.
  • [8] Kwon E.D., Drake C.G., Scher H.I. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043) : a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:700-712.
  • [9] Robert C., Long G.V., Brady B. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N Engl J Med. 2015;372:320-330.
  • [10] Weber J.S., D’Angelo S.P., Minor D. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037) : a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375-384.
  • [11] Ansell S.M., Lesokhin A.M., Borrello I. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. N Engl J Med. 2015;372:311-319.
  • [12] Brahmer J., Reckamp K.L., Baas P. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;372:123-135.
  • [13] Motzer R.J., Escudier B., McDermott D.F. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;372:1803-1813.
  • [14] Ferris R.L., Blumenschein G. Jr., Fayette J. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016.
  • [15] Le D.T., Uram J.N., Wang H. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372:2509-2520.
  • [16] Larkin J., Chiarion-Sileni V., Gonzalez R. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373:23-34.
  • [17] Postow M.A., Chesney J., Pavlick A.C. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006-2017.
  • [18] Champiat S., Lambotte O., Barreau E. Management of immune checkpoint blockade dysimmune toxicities : a collaborative position paper. Ann. Oncol. 2016;27:559-574.
  • [19] Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017 ; 28 (Suppl. 4) : iv119-42.
  • [20] Zeissig S., Petersen B.S., Tomczak M. Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4. Gut. 2015;64:1889-1897.
  • [21] Schubert D., Bode C., Kenefeck R. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20:1410-1416.
  • [22] Kuehn H.S., Ouyang W., Lo B. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014;345:1623-1627.
  • [23] Read S., Greenwald R., Izcue A. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol. 2006;177:4376-4383.
  • [24] Barnes M.J., Griseri T., Johnson A.M. CTLA-4 promotes Foxp3 induction and regulatory T cell accumulation in the intestinal lamina propria. Mucosal Immunol. 2013;6:324-334.
  • [25] Lathrop S.K., Bloom S.M., Rao S.M., Nutsch K., Lio C.W., Santacruz N., Peterson D.A., Stappenbeck T.S., Hsieh C.S. Peripheral education of the immune system by colonic commensal microbiota. Nature. 2011;478:250-254.
  • [26] Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015 ; 350 : 1079-84.
  • [27] Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015 ; 350 : 1084-9.
  • [28] Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun 2016 ; 7 : 10391.
  • [29] Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol 2017 ; 28 : 1368-79.
  • [30] Gupta A, De Felice KM, Loftus EV, Khanna S. Systematic review : colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 2015 ; 42 : 406-17.
  • [31] Horvat T.Z., Adel N.G., Dang T.O. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33:3193-3198.
  • [32] Beck K.E., Blansfield J.A., Tran K.Q. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24:2283-2289.
  • [33] Eggermont A.M., Chiarion-Sileni V., Grob J.J. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med. 2016;375:1845-1855.
  • [34] Marthey L, Mateus C, Mussini C, et al. Cancer immunotherapy with anti- CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis 2016 ; 10 : 395-401.
  • [35] Verschuren E.C., van den Eertwegh A.J., Wonders J. Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis. Clin Gastroenterol Hepatol. 2016;14:836-842.
  • [36] Arriola E, Wheater M, Karydis I, et al. Infliximab for IPILIMUMABRelated Colitis-Letter. Clinical Cancer Research 2015 ; 21 : 5642-3.
  • [37] Baroudjian B., Lourenco N., Pagès C. Anti-PD1-induced collagenous colitis in a melanoma patient. Melanoma Res. 2016;26:308-311.
  • [38] Gonzalez R.S., Salaria S.N., Bohannon C.D., Huber A.R., Feely M.M., Chanjuan Shi C. PD-1 inhibitor gastroenterocolitis : case series and appraisal of ‘immunomodulatory gastroenterocolitis’. Histopathology. 2016. 10.1111/his.13118
  • [39] Collins M, Michot JM, Danlos FX, et al. Inflammatory gastrointestinal diseases associated with PD-1 Blockade Antibodies. Ann Oncol 2017, sous presse.
  • [40] Postow MA1, Chesney J., Pavlick A.C., Robert C. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006-2017.